Dendritic cell vaccine (H. Lee Moffitt Cancer Center and Research Institute)

N/A

Report date: 2022/12/31 19:21:26

Base Information

Drug NameDendritic cell vaccine (H. Lee Moffitt Cancer Center and Research Institute)

Drug Alias NameDC-1

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccineVaccines > Application > Prophylactic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsTriple Negative Breast NeoplasmsBreast Neoplasms, MaleBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesH Lee Moffitt Cancer Center & Research Institute University Of Pennsylvania

China Registration ClassN/A

Develop Information

Active CompaniesH Lee Moffitt Cancer Center & Research Institute

Inactive CompaniesN/A

Active IndicationsTriple Negative Breast NeoplasmsBreast Neoplasms, MaleBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A